Spots Global Cancer Trial Database for Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Official Title: Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma

Study ID: NCT04405167

Conditions

Multiple Myeloma

Interventions

Tasquinimod

IRd chemotherapy

Study Description

Brief Summary: This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

Detailed Description: Tasquinimod has previously been studied as an anti-cancer agent in patients with other cancers, including a phase 3 randomized trial in patients with metastatic prostate cancer that showed an improvement in radiographic progression-free survival. The side effect profile of tasquinimod is well-characterized based on this previous experience. This trial will establish a maximum tolerated dose and optimal schedule for administration of tasquinimod in patients with multiple myeloma and then investigate the maximum tolerated dose of tasquinimod in combination with a standard myeloma regimen of ixazomib, lenalidomide, and dexamethasone (IRd). For both single agent tasquinimod and the combination of tasquinimod with IRd, exploratory expansion cohorts will be enrolled to preliminarily characterize the antimyeloma activity of each regimen.